- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about LLY
Recent news which mentions LLY
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
November 08, 2024
Tickers
LLY
From Motley Fool
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
November 07, 2024
From Benzinga
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
November 06, 2024
Tickers
LLY
From Motley Fool
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
November 06, 2024
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
November 05, 2024
From Benzinga
From Benzinga
From Benzinga
What's Going On With Hims & Hers Health Stock Monday?
November 04, 2024
From Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
November 04, 2024
From Benzinga
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
November 03, 2024
From Motley Fool
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
November 01, 2024
From Benzinga
From Benzinga
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
November 01, 2024
Tickers
LLY
From Motley Fool
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
October 31, 2024
From Benzinga
Are Eli Lilly's Lowered Expectations a Reason to Sell?
October 31, 2024
Tickers
LLY
From Motley Fool
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
October 30, 2024
From Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
From Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 30, 2024
From Benzinga
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
October 30, 2024
From Benzinga
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
October 30, 2024
From Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
October 30, 2024
From Motley Fool
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.